LONDON--(BUSINESS WIRE)--According to a recent Technavio report, the Behcet's disease therapeutics market is expected to grow by USD 224.55 million during 2019-2023. Growth in the Behcet's disease ...

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Behcet's Disease Market - A Global and Regional Analysis: Focus on Distribution Channel, Route of Administration, Type, Country, and Region - Analysis ...

Please provide your email address to receive an email when new articles are posted on . The rare and complex Behcet’s disease is often misdiagnosed or undiagnosed, leading to significant, but ...

A chronic inflammatory disease similar to canker sores that occur when fatigued, but which invades the eyes, genitals, and major organs, causing severe complications, is Behçet’s disease. It is named ...

DESTIN, Fla. — Behçet syndrome — which is classified as a vasculitis — is marked by distinct features that differentiate it from other autoimmune and autoinflammatory diseases, according to Yusuf ...

Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.

PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Behcet's Disease pipeline constitutes 4+ key companies continuously working towards developing 4+ ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the Behcet's syndrome market. The report includes a detailed analysis of the pipeline molecules under ...

Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...

Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and ...